This cohort study evaluates whether fat body mass is associated with vertebral fracture progression in postmenopausal women with early breast cancer who are undergoing adjuvant therapy with aromatase inhibitors and denosumab. This evidence concerns the gene CYP19A1 and breast carcinoma.